BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER - OCTOBER 2013)

Biosimilars: An Offset for Lofty Priced Biologics

Asim Priyendu1, Amit Kumar Singh2 & Anantha Naik Nagappa1

Introduction: Biologics are new inventions showing great promise in therapeutics especially in the area of Cancer, Rheumatoid Arthritis, Cardiovascular Diseases and HIV. Among biologics, the monoclonal antibodies (MAB) stand apart as a masterpiece of technological precision. The monoclonal antibodies are known for missile like targeted action and are almost free from the burden of ADRs and toxicities1. Moreover, they are known for guaranteed efficacy and belong to a class of molecular medicine. MABs are highly expensive and are beyond the approach of common man hence, can be used only by the super-rich. The complete regimen of a MAB runs from 20 to 40 lacs INR. The irony of MAB is that although the medicine is excellent still it is used sparingly due to very high cost (see Table-1). 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.